A clinically relevant heterozygous ATR mutation sensitizes colorectal cancer cells to replication stress.
Ontology highlight
ABSTRACT: Colorectal cancer (CRC) ranks third among the most frequent malignancies and represents the second most common cause of cancer-related deaths worldwide. By interfering with the DNA replication process of cancer cells, several chemotherapeutic molecules used in CRC therapy induce replication stress (RS). At the cellular level, this stress is managed by the ATR-CHK1 pathway, which activates the replication checkpoint. In recent years, the therapeutic value of targeting this pathway has been demonstrated. Moreover, MSI + (microsatellite instability) tumors frequently harbor a nonsense, heterozygous mutation in the ATR gene. Using isogenic HCT116 clones, we showed that this mutation of ATR sensitizes the cells to several drugs, including SN-38 (topoisomerase I inhibitor) and VE-822 (ATR inhibi
SUBMITTER: Egger T
PROVIDER: S-EPMC8971416 | biostudies-literature | 2022 Mar
REPOSITORIES: biostudies-literature
ACCESS DATA